Created/Updated: #jan2025

Glycated CD59

Summary of the Medical Article

1. Title of the Article

Glycated CD59 is a Potential Biomarker for Gestational Diabetes Mellitus.

2. First Two Authors Followed by et al

Wanying Wang, Chong Xu et al.

3. One-Line Summary of the Article

This study identifies glycated CD59 (gCD59) as an effective biomarker for diagnosing gestational diabetes mellitus (GDM), with enhanced accuracy when combined with fasting glucose levels.

4. Six Key Points from the Article

  1. Elevated gCD59 Levels: gCD59 levels were significantly higher in the GDM group (1.49 SPU) compared to the normal glucose tolerance (NGT) group (0.87 SPU).

  2. Independent Risk Factor: Multivariate analysis identified gCD59, diastolic blood pressure (DBP), and thyroid-stimulating hormone (TSH) as independent risk factors for GDM.

  3. Diagnostic Performance: The area under the curve (AUC) for gCD59 in diagnosing GDM was 0.681, with a sensitivity of 71.7% and specificity of 58.3%.

  4. Combination with Fasting Glucose: Combining gCD59 with fasting glucose improved diagnostic performance (AUC of 0.871).

  5. Subgroup Analysis: gCD59 demonstrated better diagnostic accuracy in normal and overweight BMI categories compared to obese categories.

  6. Study Scope: The study was conducted on a Chinese population, emphasizing the need for larger, multicenter studies for validation.

5. Practical Take-Home Message

gCD59 shows promise as a biomarker for early and accurate diagnosis of GDM, especially when combined with fasting glucose levels, potentially reducing reliance on cumbersome tests like OGTT.

6. Citation for the Article in Vancouver Format

Wang W, Xu C, Lu X, Cao W, Zuo T, Zhang Y, Zou H, Sun Y. Glycated CD59 is a potential biomarker for gestational diabetes mellitus. Front Endocrinol. 2024;15:1374253. doi: 10.3389/fendo.2024.1374253.